xml version="1.0" encoding="UTF-8"?        Document  

false0000078003  0000078003  us-gaap:CommonStockMember    2020-02-27 2020-02-27    0000078003  pfe:NotesDue20220.250Member    2020-02-27 2020-02-27    0000078003  pfe:NotesDue20200.000Member    2020-02-27 2020-02-27    0000078003  pfe:NotesDue20271.000Member    2020-02-27 2020-02-27    0000078003   2020-02-27 2020-02-27  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 27, 2020 

PFIZER INC.

(Exact name of registrant as specified in its charter)

[DATA_TABLE_REMOVED]

235 East 42nd Street10017

New York, New York (Zip Code)

(Address of principal executive offices)

Registrant’s telephone number, including area code:

(212) 733-2323 

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

[DATA_TABLE_REMOVED]

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Election of James Quincey to the Board of Directors

On February 27, 2020, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected James Quincey to serve as a member of the Company’s Board, effective immediately. In addition, he was appointed to the Compensation Committee and the Science and Technology Committee of the Board. 

Mr. Quincey has been provided an indemnification agreement and will receive compensation in accordance with the Company’s standard arrangements for non-employee directors. 

The press release, dated February 27, 2020, announcing the election of Mr. Quincey is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Resignation of W. Don Cornwell upon Close of the Planned Combination of Mylan N.V. and Upjohn Inc.

Also, on February 27, 2020, Pfizer Inc. announced that W. Don Cornwell, a current Pfizer board member, has agreed to join the board of directors of Viatris upon the closing of the planned combination of Mylan N.V. and Upjohn Inc., which is expected to occur in mid-2020, and will resign from the Company’s Board of Directors upon joining the Viatris board of directors.

The press release, dated February 27, 2020, announcing that Mr. Cornwell has agreed to join the Viatris board of directors, is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

[DATA_TABLE_REMOVED]

Exhibit Index

[DATA_TABLE_REMOVED]

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

[DATA_TABLE_REMOVED]